49 citations
,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
48 citations
,
September 2013 in “Oncologist” This study reported that alopecia is a common but often underreported side effect of endocrine-based cancer therapies, with tamoxifen showing the highest incidence of hair loss among analyzed treatments.
30 citations
,
July 2019 in “Endocrinology” This review discusses how the HSD3B1(1245C) genotype may impact androgen physiology and the progression of castration-resistant prostate cancer, and does not report new experimental results.
26 citations
,
September 2020 in “Journal of the European Academy of Dermatology and Venereology” This publication is a letter discussing the association between an androgen receptor genetic variant and COVID-19 disease severity in hospitalized male patients, but it reports no new research results.
23 citations
,
May 2019 in “Expert Opinion on Therapeutic Patents” This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.
5 citations
,
August 2018 This paper highlights the growing scientific interest in plant extracts for cosmetics due to their potential benefits, including antioxidant, antimicrobial, and protective properties, while emphasizing the need for quality and safety assessment to mitigate possible adverse reactions.
5 citations
,
January 2022 in “Clinical cancer investigation journal” This study suggests that certain Dibenzo derivatives may be promising candidates for prostate cancer treatment due to their potential interactions with the androgen receptor and 5α-reductase enzyme.
January 2022 in “Asian journal of Current Research in Clinical Cancer” This study reviews the potential of dibenzo derivatives as safer cancer treatments but finds conflicting evidence about their effectiveness, possibly due to structural differences among the compounds, and reports no new results.
157 citations
,
May 2021 in “Endocrine Reviews” This review discusses recent advancements in understanding and managing congenital adrenal hyperplasia, including improvements in screening, diagnostics, and potential genetic and cell-based treatments, but reports no new clinical findings.
156 citations
,
September 2021 in “Pneumologie” This review discusses the development of an interdisciplinary guideline on Post-COVID/Long-COVID symptoms, diagnostics, and therapies by the Deutsche Gesellschaft für Pneumologie, reporting no new results but highlighting ongoing updates based on emerging knowledge.
125 citations
,
September 2019 in “Journal of Clinical Immunology” This review summarizes recent advances in Treg cell biology, focusing on Foxp3's role in immune regulation and therapeutic reprogramming for immune dysregulatory disorders, but reports no new clinical results.
123 citations
,
May 2020 in “Drug Development Research” This article argues that androgen sensitivity could be a key factor in the severity of COVID-19, suggesting that trials with anti-androgen agents may be warranted.
121 citations
,
November 2020 in “Endocrine” This review discusses evidence on androgen sensitivity as a potential factor in COVID-19 disease severity, suggesting that androgen receptor interactions could influence virus entry and progression, and reports no new clinical results.
115 citations
,
June 2004 in “Pediatrics” This study found that children are susceptible to SARS-CoV, with good short- to medium-term outcomes, and that sore throat and neutrophilia can predict severe illness.
96 citations
,
December 2022 in “Pneumologie” This guideline review discusses current symptoms, diagnostic approaches, and treatments for Long- and Post-COVID, based on today's knowledge, and emphasizes its practical application with ongoing updates as new insights emerge.
85 citations
,
July 2025 in “Nature Communications” This review examines the evolving field of nanozymes, highlighting their unique properties and biocatalytic capabilities that challenge traditional concepts of biocatalysis, with implications for sustainable applications and potential roles in physiological processes and disease pathogenesis.
81 citations
,
November 2012 in “Journal of the National Cancer Institute” This study found that FLCN deficiency in mice muscles led to increased mitochondrial biogenesis and a metabolic shift towards oxidative phosphorylation, with a similar advantage observed in FLCN-null kidney cancer cells.
77 citations
,
July 2020 in “European Journal of Clinical Pharmacology” This review explores potential early-stage pharmacologic interventions for COVID-19 by targeting virus entry into host cells, identifying several existing drugs for further investigation, but reports no new clinical results.
71 citations
,
April 2020 in “Journal of Cosmetic Dermatology” This article discusses the potential link between genetic variants associated with androgen receptor activity and racial variations in COVID-19 mortality, suggesting a possible role for anti-androgens in treatment, but reports no new clinical findings.
68 citations
,
April 2014 in “Journal of Molecular Endocrinology” This review summarizes existing knowledge on androgen receptor activity in breast cancer and reports no new clinical findings, with emphasis on therapies targeting androgen signaling in specific BC subtypes.
66 citations
,
March 2018 in “British journal of dermatology/British journal of dermatology, Supplement” This article reviews the role of perifollicular regulatory T cells in maintaining hair follicle integrity in the context of hidradenitis suppurativa and calls attention to inflammatory mechanisms without reporting new clinical results.
59 citations
,
October 2020 in “Stem Cell Reviews and Reports” This review discusses potential mechanisms contributing to higher COVID-19 mortality among men, particularly the roles of smoking, genetic factors, and reproductive hormones, without presenting new clinical findings.
59 citations
,
April 2016 in “Breast Cancer Research and Treatment” This study found that AR/VDR-targeted agonist hormone therapy can inhibit cell viability in HR2-av triple-negative breast cancer cell lines through multiple mechanisms and may enhance the effects of chemotherapy.
58 citations
,
December 2020 in “Mayo Clinic Proceedings” This paper discusses the variability in COVID-19 susceptibility and severity, emphasizing factors like biological differences and suggesting potential precision medicine approaches, but it reports no new clinical results.
54 citations
,
October 2023 in “Oncogene” In this review, the researchers detailed how the p63 transcription factor influences epithelial stem cell activities such as self-renewal, differentiation, and proliferation, highlighting the role of TAp63 and ΔNp63 isoforms in both normal tissue development and cancer pathogenesis.
51 citations
,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.
49 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” This study found that combining cyproterone acetate with testosterone enanthate was highly effective in suppressing spermatogenesis, suggesting potential as a reversible male contraceptive method.
47 citations
,
April 2020 in “Dermatologic Therapy” This letter discusses the potential connection between androgenetic alopecia and COVID-19, suggesting a possible new therapy, but it reports no new results.
46 citations
,
August 2022 in “Journal of Endocrinological Investigation” In this study, the authors concluded that COVID-19 may not cause direct long-term harm to testicular function, but temporary indirect effects could occur, suggesting a possible delay in pursuing parenthood post-recovery.
45 citations
,
January 2020 in “International Journal of Molecular Sciences” This review discusses the potential of plant polyphenols to overcome multidrug resistance in various solid cancers and reports no new experimental results; further research is suggested.